RxDoctor Payments Data

Stephen Cherry, MD

Cardiovascular Disease · Boone, NCNPI 1346217247

Payments from drug & device makers

$4,940in general payments, 2019–2025

Across 157 payments — averaging $31.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • AstraZeneca$423
  • Merck$327
  • Philips North America LLC$319
  • Boehringer Ingelheim$303
  • E.r. Squibb & Sons, L.L.C.$281
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,27899%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,940 in reported general payments places this provider in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$45,659
Medicare patients
363
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$72,804
JardianceEmpagliflozin62$53,064
EntrestoSacubitril/Valsartan14$16,646
FarxigaDapagliflozin Propanediol18$12,513
XareltoRivaroxaban11$5,914
Metoprolol Succinate80$1,318
Nitroglycerin74$1,249
Rosuvastatin Calcium71$1,218
Atorvastatin Calcium148$1,186
Ranolazine ErRanolazine13$1,125
Potassium Chloride29$1,033
Metoprolol Tartrate193$993
Midodrine Hcl13$674
Amlodipine Besylate85$614
Carvedilol73$553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$197$72,80488 claims
Boehringer IngelheimJardiance$303$53,06462 claims
NovartisEntresto$270$16,64614 claims
AstraZenecaFarxiga$423$12,51318 claims
Johnson & JohnsonXarelto$237$5,91411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Boone

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →